narcolepsy
NARCOLEPSY

Narcolepsy is a chronic neurologic sleep disorder wherein the patient have excessive daytime sleepiness and rapid eye movement sleep is dysregulated.

It affects 1 in 1000 individuals, with prevalence of about 0.04% of general population.
The exact cause remains unclear.
Studies suggest a combination of genetic predisposition, abnormal neurotransmitter functioning and abnormal immune modulation.
Symptoms include excessive daytime sleepiness, cataplexy, sleep paralysis, sleep-related hallucinations, automatic behavior, fragmented nocturnal sleep and insomnia.

Narcolepsy Drug Information

Drug Information

Indication: Attention deficit hyperactivity disorder (ADHD).

Indication: Depression including depression w/ associated anxiety. Generalized anxiety disorder (GAD) including long-term ...

Indication: Depressive illness, symptoms of depressive disorder & obsessive compulsive disorder (OCD).

Indication: Depression, obsessive-compulsive disorder, premenstrual dysphoric disorder (PMDD).

Indication: Symptomatic treatment of depression w/ or w/o anxiety. Obsessive compulsive disorder, pre-menstrual dysphoric ...

Indication: ADHD, narcolepsy.

Indication: Depression. Bulimia nervosa.

Indication: Major depressive disorder, panic disorder w/ or w/o agoraphobia, premenstrual dysphoric disorder, social anxie...

Indication: ADHD in childn ≥6 yr, adolescents & adults.

1  /  3
Editor's Recommendations
Most Read Articles
Pearl Toh, 03 Jul 2020
After treatment with fremanezumab, a difficult-to-treat patient population with treatment-resistant episodic or chronic migraine saw sustained benefits across a broad range of measures, according to multiple analyses of the FOCUS study released during the AHS 2020 Virtual Meeting.
Pearl Toh, 24 Jun 2020
While aducanumab significantly reduced clinical decline in individuals with early Alzheimer's disease (AD) in one randomized trial, no changes were seen in another identical study — rendering the role of aducanumab in AD inconclusive.
Elvira Manzano, 24 Oct 2018
New evidence showed that a high-fat, low-carbohydrate ketogenic diet could help improve symptoms in patients with Parkinson's disease (PD), so did a low-fat, high-carbohydrate diet.
Pearl Toh, 01 Jul 2020
The CGRP* receptor blocker erenumab shows sustained efficacy in reducing migraine frequency over 2 years in a difficult-to-treat patient population with episodic migraine who had failed 2–4 prior preventive treatments, an interim analysis of the LIBERTY** open-label extension study shows.